A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).

被引：0
|
作者：
Pan, Chong-xian
Lara, Primo
Evans, Christopher P.
Parikh, Mamta
White, Ralph de Vere
Dall'era, Marc
Liu, Chengfei
Robles, Daniel
Gao, Allen
机构：
[1] Univ Calif Davis Comprehens Canc Ctr, Sacramento, CA USA
[2] Univ Calif Davis, Sacramento, CA USA
[3] Pandomedx Inc, Davis, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.TPS394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS394
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase Ib trial of enzalutamide with oral decitabine/cedazuridine in metastatic castration-resistant prostate cancer (CRPC).
    Roy, Arya Mariam
    Gopalakrishnan, Dharmesh
    Jatwani, Karan
    Green, Kelly
    Farmer, Bailey
    Jaiswal, Neha
    Attwood, Kristopher
    Levine, Ellis Glenn
    Beltran, Himisha
    Goodrich, David
    Chatta, Gurkamal S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS252 - TPS252
  • [2] A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC)
    Leibrandt, Ryan
    Ullah, Ayman Teeham
    Verma, Rashmi
    Gao, Allen
    Lara, Primo N., Jr.
    Pan, Chong-xian
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] COMBINATION OF INDOMETHACIN AND ENZALUTAMIDE TO TREAT CASTRATION-RESISTANT PROSTATE CANCER
    Liu, Chengfei
    Lou, Wei
    Pan, Chong-xian
    Lara, Primo
    Evans, Christopher
    Parikh, Mamta
    White, Ralph deVere
    Dall'Era, Marc
    Gao, Allen
    JOURNAL OF UROLOGY, 2018, 199 (04): : E694 - E694
  • [4] A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).
    Gopalakrishnan, Dharmesh
    Kirk, Jason
    Davis, John
    George, Saby
    Levine, Ellis Glenn
    Beumer, Jan Hendrik
    Appleman, Leonard Joseph
    Tang, Dean
    Chatta, Gurkamal S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC)
    Rathkopf, D. E.
    Chi, K. N.
    Vaishampayan, U.
    Hotte, S.
    Vogelzang, N.
    Alumkal, J.
    Agrawal, M.
    Nydam, T. M.
    Fandi, A.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
  • [7] Enzalutamide in Castration-Resistant Prostate Cancer
    Anker, Markus S.
    Lehmann, Lorenz H.
    Anker, Stefan D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14): : 1380 - 1380
  • [8] Enzalutamide in castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2014, 15 (08): : E312 - E312
  • [9] Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
    Morris, Michael J.
    Rathkopf, Dana E.
    Novotny, William
    Gibbons, Jacqueline A.
    Peterson, Amy C.
    Khondker, Zakaria
    Ouatas, Taoufik
    Scher, Howard I.
    Fleming, Mark T.
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3774 - 3781
  • [10] Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)
    Kong, Yifan
    Cheng, Lijun
    Mao, Fengyi
    Zhang, Zhuangzhuang
    Zhang, Yanquan
    Farah, Elia
    Bosler, Jacob
    Bai, Yunfeng
    Ahmad, Nihal
    Kuang, Shihuan
    Li, Lang
    Liu, Xiaoqi
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (37) : 14328 - 14341
12345